The question of what the accepted therapeutic strategies for de-intensification in low-risk, HPV-related oropharyngeal squamous cell carcinoma are will be debated in an upcoming discussion.
In thyroid cancer, molecular diagnostic tests enable oncologists to evaluate thyroid nodules with atypical, suspicious, or indeterminate fine-needle aspiration cytology to determine the best course of treatment based on cytopathological result.
Patients with differentiated thyroid cancer who were felt to not have a choice in receiving radioactive iodine treatment reportedly had lower satisfaction with the treatment decision, suggesting a need for increased shared decision making between physicians and patients.
Among patients with medullary thyroid cancer, PD-L1 positive status is linked to more aggressive clinicopathological features and predictive of structural and biochemical recurrences.
The FDA has approved pembrolizumab (Keytruda) for the first-line treatment of patients with metastatic or unresectable recurrent head and neck squamous cell carcinoma as monotherapy whose tumors express PD-L1 (composite positive score [CPS] ≥1) and also in combination with platinum and fluorouracil (FU) for this patient population, irrespective of PD-L1 expression.
In an effort to build more sophisticated protocols that keep QoL and cost questions at the forefront, Montefiore Einstein Center for Cancer Care and
Albert Einstein College of Medicine’s Institute for Onco-Physics created a mathematical model to identify the optimal candidates for proton therapy, the most modern form of radiation therapy for patients with head and neck cancers.
A new staging system for head and neck cancers recognizes that patients with oropharyngeal malignancies associated with the human papillomavirus often have an excellent prognosis, but efforts to deintensify therapy for this population based on a fresh understanding of favorable risk factors may be premature.
Fee-for-service tends to result in a surplus of care and unnecessary medical expense, but it probably won’t disappear from the landscape soon.
The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion for a new extended dosing schedule for pembrolizumab for all of the PD-1 inhibitor’s monotherapy indications in the European Union.
A recently launched clinical trial aims to improve outcomes and quality of life for patients with nasal and paranasal squamous cell carcinoma (NPNSCC), a rare type of head and neck cancer that is challenging to treat and carries significant morbidity.